SF1126 is an integrin-targeted PI3 kinase inhibitor.
- Mechanism
- Curator reviewed
SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class IA isoforms and other key members of the PI3K superfamily, including DNA-PK and mTOR. A major factor in tumor resistance to approved chemotherapy agents is thought to be the activation of the PI3K/PTEN pathway. As a result, it is thought that inhibiting this pathway, via SF1126, could cause the resetting of sensitivity to approved agents and exhibit synergistic anticancer effects.
- Primary indication
- For the treatment of various forms of cancer.Curator reviewed
- Code names
- SF1126
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with SF1126, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account